Misoprostol and Mifepristone Access - Patient and Provider Reporting Form

Background

The New Orleans City Council passed a unanimous motion on September 18, 2024, to task the New Orleans Health Department (“NOHD”) to investigate and study any delay of care issues that result from Act 246, which classifies mifepristone and misoprostol as scheduled drugs effective October 1, 2024. 

The intent of this form is to allow the NOHD to understand the impacts of ACT 246 throughout the City of New Orleans. Such impacts would include identifying challenges to legal and medically necessary access to mifepristone and misoprostol through a health care provider and/or pharmacist.

Any information provided on this form will be kept strictly confidential. Please do not include protected health information (i.e., medical records, diagnosis, treatment, etc.), unless you are the patient and are willing to self-disclose to NOHD for the purpose of follow up.

Disclaimer: NOHD is a HIPAA covered entity and is subject to privacy and security regulations.

Evaluation Report

Evaluating the Impact of Act 246 of the 2024 Louisiana Legislative Session: The Classification of Misoprostol and Mifepristone as Schedule IV Controlled Dangerous Substances, September 2025

Download PDF of report

Resources

For Patients

Locate a pharmacy that distributes misoprostol with a valid prescription near you.

List of Orleans and Jefferson Parish pharmacies with misoprostol

Map of New Orleans pharmacies

For Pharmacists and Health Care Providers

Act 246 Louisiana Pharmacist Compliance Guide

Patient and Provider Reporting Form

2. Please select the option that best describes you:  *:
Follow-up is completely optional at your discretion. If yes, please share your name and preferred contact method. 

Pages in this section